Which GLP-1 is Approved for Weight Loss?

Last reviewed: May 15, 2026 Last updated: May 15, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Two prescription medications now carry FDA approval specifically for chronic weight management in adults. Semaglutide and tirzepatide represent a major shift in how healthcare providers approach obesity treatment. PlexusDx offers access to compounded versions of both medications through licensed 503A pharmacies.

Understanding GLP-1 Receptor Agonists and Weight Loss

GLP-1 receptor agonists are a class of injectable medications originally developed to help people with type 2 diabetes control blood sugar. These drugs mimic glucagon-like peptide-1 (GLP-1), a natural hormone in the body that regulates appetite and blood glucose levels. Over the past five years, clinical research demonstrated that these medications also produce substantial weight loss in people without diabetes.

The mechanism behind weight loss is straightforward: GLP-1 agonists slow how quickly food moves through the stomach, increase feelings of fullness after eating smaller portions, and signal the brain to reduce hunger. This triple action makes it easier for patients to maintain a calorie deficit without feeling constantly deprived. The effect is sustained as long as the medication is taken consistently.

How GLP-1 Medications Work in Your Body

When you inject a GLP-1 receptor agonist, the medication binds to GLP-1 receptors throughout your digestive system and brain. This activation triggers several simultaneous changes: your stomach empties more slowly, sending prolonged satiety signals to your hypothalamus (the brain's appetite center), and your pancreas adjusts insulin release to maintain stable blood sugar. Together, these effects reduce overall calorie intake by 20–30% without requiring constant willpower.

Individual responses vary based on genetics, metabolism, and lifestyle factors. The Precision Peptide Genetic Test from PlexusDx analyzes predispositions in peptide genetic pathways—including variants in GLP1R, GIPR, FTO, and MC4R—to help identify which medication class may work optimally for your unique biology. This personalized approach increases the likelihood of sustained success compared to one-size-fits-all treatment.

FDA-Approved GLP-1 Medications for Weight Management

Semaglutide received FDA approval for chronic weight management under the brand name Wegovy in November 2021. Clinical trials (the STEP program) showed that adults receiving semaglutide lost an average of 15% of their starting body weight over 68 weeks, compared to 2.4% for placebo. The medication is administered via once-weekly subcutaneous injection, with doses ranging from 0.25 mg to 2.4 mg weekly. PlexusDx offers compounded semaglutide injections starting at $149 per month, as well as oral formulations beginning at $209 monthly.

Tirzepatide became FDA-approved for weight loss under the brand name Zepbound in November 2023, following the SURMOUNT trials. These studies demonstrated even greater weight reduction, with participants losing up to 22% of baseline body weight at the highest dose. Tirzepatide acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, providing dual activation compared to semaglutide's single-pathway action. PlexusDx compounded tirzepatide injections range from $249 monthly, with oral options from $279 per month.

Compounded vs. Brand-Name GLP-1 Options

Brand-name semaglutide (Wegovy) and tirzepatide (Zepbound) are mass-manufactured by large pharmaceutical companies and distributed through traditional retail pharmacies. These FDA-approved products typically cost $900–$1,300 monthly without insurance coverage. Many patients face supply shortages, prior authorization delays, or coverage denials that can interrupt treatment for weeks.

PlexusDx compounded medications are manufactured by licensed 503A compounding pharmacies, which are permitted to prepare individualized medications under strict quality oversight. Compounded semaglutide and tirzepatide contain identical active pharmaceutical ingredients as their brand-name counterparts, but cost 60–75% less. PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization. HSA and FSA accounts are eligible for payment. For patients seeking lower-cost entry, the Microdose GLP-1 Protocol starts at just $129 per month.

Weight Loss Results and Metabolic Health Benefits

The weight loss achieved with FDA-approved GLP-1 medications translates into measurable health gains. The STEP and SURMOUNT trials documented reductions in blood pressure, improvements in cholesterol profiles, and better glycemic control—even in non-diabetic participants. Patients reported increased energy, improved mobility, reduced joint pain, and better sleep quality. These metabolic improvements often appear before significant scale weight changes, signaling early benefits from the medication.

Beyond numbers on a scale, sustained weight loss lowers the risk of cardiovascular disease, type 2 diabetes, certain cancers, and sleep apnea. Quality-of-life surveys show that GLP-1 users report greater confidence in social situations, improved body image, and reduced food-related anxiety. Long-term adherence requires ongoing medication use; weight typically returns within 12 months after discontinuation, underscoring that GLP-1 therapy is best viewed as a chronic management tool similar to blood pressure or cholesterol medication.

Frequently Asked Questions About Which GLP-1 is Approved for Weight Loss?

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.